Premium
Amnioinfusion in very early preterm prelabor rupture of membranes ( AMIPROM ): pregnancy, neonatal and maternal outcomes in a randomized controlled pilot study
Author(s) -
Roberts D.,
Vause S.,
Martin W.,
Green P.,
Walkinshaw S.,
Bricker L.,
Beardsmore C.,
Shaw N.,
McKay A.,
Skotny G.,
Williamson P.,
Alfirevic Z.
Publication year - 2014
Publication title -
ultrasound in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.202
H-Index - 141
eISSN - 1469-0705
pISSN - 0960-7692
DOI - 10.1002/uog.13258
Subject(s) - medicine , amnioinfusion , randomized controlled trial , gestational age , obstetrics , gestation , pregnancy , rupture of membranes , bayley scales of infant development , randomization , premature rupture of membranes , pediatrics , oligohydramnios , surgery , cognition , psychiatry , biology , genetics , psychomotor learning
Objective To assess short‐ and long‐term outcomes of pregnant women with very early rupture of membranes randomized to serial amnioinfusion or expectant management, and to collect data to inform a larger, more definitive clinical trial. Methods This was a prospective non‐blinded randomized controlled trial with randomization stratified for pregnancies in which the membranes ruptured between 16 + 0 and 19 + 6 weeks' gestation and 20 + 0 and 23 + 6 weeks' gestation to minimize the risk of random imbalance in gestational age distribution between randomized groups. Intention‐to‐treat analysis was used. The study was conducted in four UK hospital‐based fetal medicine units (Liverpool Women's NHS Trust, St Mary's Hospital Manchester, Birmingham Women's NHS Foundation Trust and Wirral University Hospitals Trust). The participants were women with confirmed preterm prelabor rupture of membranes at 16 + 0 to 24 + 0 weeks' gestation. Women with multiple pregnancy, fetal abnormality or obstetric indication for immediate delivery were excluded. Participants were randomly allocated to either serial weekly transabdominal amnioinfusions if the deepest pool of amniotic fluid was < 2 cm or expectant management until 37 weeks' gestation. Short‐term maternal, pregnancy and neonatal and long‐term outcomes for the child were studied. Long‐term respiratory morbidity was assessed using validated respiratory questionnaires at 6, 12 and 18 months of age and infant lung function test at around 12 months of age. Neurodevelopment was assessed using the Bayley Scales of Infant Development, second edition (BSID‐II) at corrected age of 2 years. Results Fifty‐eight women were randomized to the study. Two babies were excluded from the analysis because of termination of pregnancy for lethal anomaly, leaving 56 participants (28 assigned to serial amnioinfusion and 28 to expectant management) recruited between 2002 and 2009. There was no significant difference in perinatal mortality (19/28 vs 19/28; relative risk ( RR ) 1.0 (95% CI , 0.70–1.43)) and maternal or neonatal morbidity. The overall chance of surviving without long‐term respiratory or neurodevelopmental disability was 4/56 (7.1%); 4/28 (14.3%) in the amnioinfusion group and 0/28 in the expectant group ( RR 9.0 (95% CI , 0.51–159.70)). Conclusions This pilot study found no major differences in maternal, perinatal or pregnancy outcomes. The study was not designed to show a difference between the groups and the number of survivors was too small to draw any conclusions about long‐term outcomes. It does, however, signal that a larger definitive study to evaluate amnioinfusion for improvement in healthy survival is needed. The pilot suggests that, with appropriate funding, such a study is feasible. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.